ライフサイエンスコーパス: romosozumab

1 nists and 1.56, 1.02 to 2.39 for denosumab v romosozumab).

2 oice response system to receive subcutaneous romosozumab (210 mg once monthly) or subcutaneous teripa

3 a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg)

4 y nonrecurring injection-site reactions with romosozumab, adverse events were similar among groups.

5 We compared the effects of 12 months of romosozumab (AMG 785), a sclerostin monoclonal antibody,

6 events were reported in 17 (8%) patients on romosozumab and in 23 (11%) on teriparatide; none were j

7 Romosozumab, approved by the FDA in 2019, is a humanized

8 The monoclonal antibody romosozumab binds to sclerostin and increases bone forma

9 paratide) and sclerostin inhibitors (such as romosozumab) can be considered for very high-risk indivi

10 , parathyroid hormone receptor agonists, and romosozumab compared with placebo.

11 th parathyroid hormone receptor agonists and romosozumab, denosumab was less effective in reducing cl

12 real BMD was 2.6% (95% CI 2.2 to 3.0) in the romosozumab group and -0.6% (-1.0 to -0.2) in the teripa

13 206 patients in the romosozumab group and 209 in the teriparatide group were

14 There were six (3%) patients in the romosozumab group compared with 12 (6%) in the teriparat

15 were nasopharyngitis (28 [13%] of 218 in the romosozumab group vs 22 [10%] of 214 in the teriparatide

16 Romosozumab is a monoclonal antibody that binds to and i

17 In such patients, romosozumab led to gains in hip BMD that were not observ

18 re randomly assigned to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210

19 2014, 436 patients were randomly assigned to romosozumab (n=218) or teriparatide (n=218).

20 s from patients with rare bone diseases (eg, romosozumab, odanacatib).

21 udy, we evaluated the efficacy and safety of romosozumab over a 12-month period in 419 postmenopausal

22 te group, representing a 27% lower risk with romosozumab (P<0.001).

23 edications (teriparatide, abaloparatide, and romosozumab) should be considered in very high-risk indi

24 adverse events were observed more often with romosozumab than with alendronate (50 of 2040 patients [

25 steonecrosis of the jaw (1 event each in the romosozumab-to-alendronate and alendronate-to-alendronat

26 new vertebral fractures was observed in the romosozumab-to-alendronate group (6.2% [127 of 2046 pati

27 nvertebral fractures was lower by 19% in the romosozumab-to-alendronate group than in the alendronate

28 curred in 198 of 2046 patients (9.7%) in the romosozumab-to-alendronate group versus 266 of 2047 pati

29 oporosis who were at high risk for fracture, romosozumab treatment for 12 months followed by alendron

30 Romosozumab was also associated with large increases in

31 In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral d

32 All dose levels of romosozumab were associated with significant increases i

33 , parathyroid hormone receptor agonists, and romosozumab were more effective than oral bisphosphonate